Web-based Automated Imaging Differentiation of Parkinsonism

基于网络的帕金森病自动成像鉴别

• 批准号: 10685065
• 负责人: Angelos Barmpoutis
• 金额: $ 7.62万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10685065
• 关键词: Algorithms; American; Area Under Curve; Autopsy; Biological Markers; Blinded; Brain; Clinic; Clinical; Clinical Trials; Communities; Data; Data Analyses; Data Collection; Dementia; Diagnosis; Diagnostic; Differential Diagnosis; Diffusion; Diffusion Magnetic Resonance Imaging; Disease; Enrollment; Goals; Growth; Health; Image; Machine Learning; Magnetic Resonance Imaging; Modeling; Motor; Movement Disorders; Multiple System Atrophy; Nerve Degeneration; Neurologic; Neurologist; Online Systems; Outcome; Parkinson Disease; Parkinsonian Disorders; Participant; Pathologic; Pathology; Patient Care; Patients; Persons; Pharmaceutical Preparations; Phase II Clinical Trials; Phase III Clinical Trials; Probability; Procedures; Process; Prognosis; Progressive Supranuclear Palsy; Prospective cohort; Protocols documentation; Radiology Specialty; Reading; Research Personnel; Risk; Secure; Signal Transduction; Site; Software Tools; System; Techniques; Testing; TimeLine; Tissues; Training; Translating; Validation; Variant; Vendor; Water; accurate diagnosis; algorithm development; atypical parkinsonism; clinical diagnosis; cohort; data exchange; diagnostic accuracy; diagnostic algorithm; diagnostic biomarker; diagnostic criteria; disease diagnosis; dopamine transporter; experience; imaging biomarker; improved; indexing; individualized medicine; innovation; performance tests; programs; quality assurance; support vector machine; tool; treatment planning; web site

SUMMARY Across the globe, there has been a considerable growth in the number of people diagnosed with Parkinsonism. Estimates indicate that from 1990 to 2015 the number of Parkinsonism diagnoses doubled, with more than 6 million people currently carrying the diagnosis, and by year 2040, 12 and 14.2 million people will be diagnosed with Parkinsonism. Parkinson’s disease (PD), multiple system atrophy Parkinsonian variant (MSAp), and progressive supranuclear palsy (PSP) are neurodegenerative forms of Parkinsonism, which can be difficult to diagnose as they share similar motor and non-motor features, and they each have an increased chance of developing dementia. In the first five years of a PD diagnosis, about 58% of PD are misdiagnosed, and of these misdiagnoses about half have either MSA or PSP. Since PD, MSAp, and PSP require unique treatment plans and different medications, and clinical trials testing new medications require the correct diagnosis, there is an urgent need for both clinic ready and clinical-trial ready markers for differential diagnosis of PD, MSAp, and PSP. Over the past decade, we have developed diffusion imaging as an innovative biomarker for differentiating PD, MSAp, and PSP. In this proposal, we will leverage our extensive experience to create a web-based software tool that can process diffusion imaging data from anywhere in the world. We will disseminate and test the tool in the largest prospective cohort of participants with Parkinsonism (PD, MSAp, PSP), working closely with the Parkinson Study Group. The reason to test this in the Parkinson Study Group network, is because they are the community that evaluates Phase II and Phase III clinical trials in Parkinsonism. This web-based software tool will be capable of reading raw diffusion imaging data, performing quality assurance procedures, analyzing the data using a validated pipeline, and providing imaging metrics and diagnostic probability. We will test the performance of the wAID-P by enrolling 315 total subjects (105 PD, 105 MSAp, 105 PSP) across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis. We will also enroll a portion of the cohort into a brain bank to ascertain pathological confirmation and to test the algorithm against cases with post-mortem diagnoses. The final outcome will be to disseminate a validated diagnostic algorithm to the Parkinson neurological and radiological community and to make it available to all on a website.

概括 在全球范围内，被诊断出患有帕金森氏症的人数已经有所增长。 估计表明，从1990年到2015年，帕金森主义诊断的数量翻了一番，超过6 将被诊断为诊断，到2040年，120万人将被诊断 与帕金森主义。帕金森氏病（PD），多系统萎缩帕金森氏症（MSAP）和 进行性上腹部麻痹（PSP）是帕金森主义的神经退行性形式，这可能很难 诊断在共享相似的电动机和非运动功能的情况下进行诊断，并且每个人都有增加的机会 发展痴呆症。在PD诊断的头五年中，约有58％的PD被误诊了，其中 误诊约一半的MSA或PSP。由于PD，MSAP和PSP需要独特的治疗计划 以及不同的药物以及测试新药物的临床试验需要正确的诊断，有一个 迫切需要PD，MSAP和PSP的鉴别诊断诊断诊所的临床准备和临床预审标记。 在过去的十年中，我们开发了差异成像，作为用于区分PD的创新生物标志物， MSAP和PSP。在此建议中，我们将利用我们的丰富经验来创建基于网络的软件工具 这可以处理来自世界任何地方的扩散成像数据。我们将在 帕金森主义（PD，MSAP，PSP）最大的前瞻性参与者队列，与The紧密合作 帕金森研究小组。在帕金森研究小组网络中对此进行测试的原因是因为它们是 评估帕金森氏症中II期和III期临床试验的社区。这个基于网络的软件工具 将能够读取原始扩散成像数据，执行质量保证程序，分析 使用经过验证的管道数据，并提供成像指标和诊断概率。我们将测试 通过在21个站点中注册315名受试者（105 pd，105 msap，105 psp）来表现WIAD-P的性能 帕金森研究小组。每个站点将执行成像，临床尺度，诊断，并将数据上传到 基于Web的软件工具。临床诊断将对诊断算法和成像视而不见 将诊断与受过训练的神经科医生诊断的运动障碍进行比较。我们还将注册一部分 该队列进入脑库以确定病理确认并测试该算法 验证后诊断。最终结果是将经过验证的诊断算法传播到 帕金森神经和放射学界，并将其用于网站上的所有人。